Comments
Loading...

Pfizer Analyst Ratings

PFENYSE
Logo brought to you by Benzinga Data
$22.92
0.140.61%
At close: -
$22.98
0.060.26%
After Hours: Apr 25, 7:58 PM EDT
The dividend Ex-Date is in 12 days
Q1 2025 earnings tomorrow on Tue Apr 29th before the market open
Conference call scheduled tomorrow at 10:00 AM Click to view the webcast
Consensus Rating1
Neutral
Highest Price Target1
$50.00
Lowest Price Target1
$24.00
Consensus Price Target1
$33.27

Pfizer Analyst Ratings and Price Targets | NYSE:PFE | Benzinga

Pfizer Inc has a consensus price target of $33.27 based on the ratings of 24 analysts. The high is $50 issued by HSBC on July 14, 2023. The low is $24 issued by Cantor Fitzgerald on April 22, 2025. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, UBS, and Goldman Sachs on April 22, 2025, April 8, 2025, and April 8, 2025, respectively. With an average price target of $24.33 between Cantor Fitzgerald, UBS, and Goldman Sachs, there's an implied 5.89% upside for Pfizer Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
1
Dec 24
2
Jan
1
1
Feb
2
Mar
3
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.6
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
UBS
Goldman Sachs
UBS
Citigroup

1calculated from analyst ratings

Analyst Ratings for Pfizer

Buy NowGet Alert
04/22/2025Buy Now4.44%Cantor Fitzgerald
Carter Gould59%
→ $24Initiates → NeutralGet Alert
04/08/2025Buy Now4.44%UBS
Trung Huynh66%
$28 → $24MaintainsNeutralGet Alert
04/08/2025Buy Now8.79%Goldman Sachs
Asad Haider 62%
$32 → $25DowngradeBuy → NeutralGet Alert
03/18/2025Buy NowGuggenheim
Vamil Divan75%
ReiteratesBuy → BuyGet Alert
03/12/2025Buy NowGuggenheim
Vamil Divan75%
ReiteratesBuy → BuyGet Alert
02/10/2025Buy Now43.61%Guggenheim
Vamil Divan75%
$33 → $33ReiteratesBuy → BuyGet Alert
02/05/2025Buy Now21.85%UBS
Colin Bristow39%
$29 → $28MaintainsNeutralGet Alert
01/28/2025Buy Now26.2%Citigroup
Andrew Baum70%
$30 → $29MaintainsNeutralGet Alert
01/08/2025Buy Now26.2%UBS
Colin Bristow39%
$31 → $29MaintainsNeutralGet Alert
12/18/2024Buy Now39.25%Truist Securities
Srikripa Devarakonda44%
$36 → $32MaintainsBuyGet Alert
12/11/2024Buy Now43.61%Guggenheim
Vamil Divan75%
$35 → $33MaintainsBuyGet Alert
12/10/2024Buy Now26.2%B of A Securities
Tim Anderson55%
→ $29Reinstates → NeutralGet Alert
11/15/2024Buy Now8.79%Wolfe Research
Alexandria Hammond46%
→ $25Initiates → UnderperformGet Alert
10/30/2024Buy Now34.9%Morgan Stanley
Terence Flynn66%
$30 → $31MaintainsEqual-WeightGet Alert
10/25/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
10/23/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
10/17/2024Buy Now39.25%Bernstein
Courtney Breen1%
→ $32Initiates → Market PerformGet Alert
10/11/2024Buy Now30.55%Morgan Stanley
Terence Flynn66%
$31 → $30MaintainsEqual-WeightGet Alert
10/03/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
09/16/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
08/19/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
08/08/2024Buy Now47.96%Daiwa Capital
Narumi Nakagiri23%
$28 → $34UpgradeNeutral → OutperformGet Alert
07/31/2024Buy Now34.9%Morgan Stanley
Terence Flynn66%
$29 → $31MaintainsEqual-WeightGet Alert
07/31/2024Buy Now39.25%Barclays
Carter Gould59%
$30 → $32MaintainsEqual-WeightGet Alert
07/31/2024Buy Now30.55%Wells Fargo
Mohit Bansal70%
$28 → $30MaintainsEqual-WeightGet Alert
07/31/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
07/31/2024Buy Now34.9%UBS
Colin Bristow39%
$30 → $31MaintainsNeutralGet Alert
07/12/2024Buy Now30.55%UBS
Colin Bristow39%
$28 → $30MaintainsNeutralGet Alert
07/10/2024Buy Now30.55%Barclays
Carter Gould59%
$28 → $30MaintainsEqual-WeightGet Alert
07/10/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
07/01/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/26/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/20/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
06/17/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
05/02/2024Buy Now26.2%Morgan Stanley
Terence Flynn66%
$28 → $29MaintainsEqual-WeightGet Alert
05/02/2024Buy Now56.66%BMO Capital
Evan David Seigerman45%
$33 → $36ReiteratesOutperform → OutperformGet Alert
04/18/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/15/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/05/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
04/01/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/31/2024Buy Now26.2%Morgan Stanley
Terence Flynn66%
$28 → $29MaintainsEqual-WeightGet Alert
03/22/2024Buy NowArgus Research
David Toung71%
DowngradeBuy → HoldGet Alert
03/04/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/01/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
02/23/2024Buy Now56.66%Guggenheim
Vamil Divan75%
→ $36Initiates → BuyGet Alert
01/31/2024Buy Now21.85%UBS
Colin Bristow39%
$29 → $28MaintainsNeutralGet Alert
01/31/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
01/17/2024Buy Now26.2%UBS
Colin Bristow39%
$27 → $29MaintainsNeutralGet Alert
01/09/2024Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$45 → $45ReiteratesOverweight → OverweightGet Alert
01/04/2024Buy Now39.25%TD Cowen
Steve Scala68%
→ $32DowngradeOutperform → Market PerformGet Alert
12/14/2023Buy Now21.85%Wells Fargo
Mohit Bansal70%
$35 → $28MaintainsEqual-WeightGet Alert
12/14/2023Buy Now95.83%Cantor Fitzgerald
Louise Chen54%
$75 → $45MaintainsOverweightGet Alert
12/14/2023Buy Now56.66%Truist Securities
Robyn Karnauskas55%
$42 → $36MaintainsBuyGet Alert
12/14/2023Buy Now17.5%UBS
Colin Bristow39%
$34 → $27MaintainsNeutralGet Alert
12/14/2023Buy Now21.85%Barclays
Carter Gould59%
$34 → $28MaintainsEqual-WeightGet Alert
12/04/2023Buy Now82.77%Truist Securities
Robyn Karnauskas55%
→ $42ReiteratesBuy → BuyGet Alert
11/20/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75ReiteratesOverweight → OverweightGet Alert
11/01/2023Buy Now47.96%Barclays
Carter Gould59%
$35 → $34MaintainsEqual-WeightGet Alert
11/01/2023Buy Now61.01%Morgan Stanley
Terence Flynn66%
$39 → $37MaintainsEqual-WeightGet Alert
10/20/2023Buy Now47.96%UBS
Colin Bristow39%
$36 → $34AssumesNeutral → NeutralGet Alert
10/17/2023Buy Now82.77%Truist Securities
Robyn Karnauskas55%
$62 → $42MaintainsBuyGet Alert
10/17/2023Buy Now69.72%Morgan Stanley
Terence Flynn66%
$40 → $39MaintainsEqual-WeightGet Alert
10/17/2023Buy Now52.31%Wells Fargo
Mohit Bansal70%
$39 → $35MaintainsEqual-WeightGet Alert
10/16/2023Buy Now43.61%BMO Capital
Evan David Seigerman45%
$44 → $33MaintainsOutperformGet Alert
10/16/2023Buy Now52.31%Citigroup
Andrew Baum70%
$42 → $35MaintainsNeutralGet Alert
10/16/2023Buy Now47.96%JP Morgan
Chris Schott59%
$36 → $34MaintainsNeutralGet Alert
10/16/2023Buy Now52.31%Wells Fargo
Mohit Bansal70%
$39 → $35MaintainsEqual-WeightGet Alert
10/16/2023Buy Now69.72%Jefferies
Akash Tewari43%
$38 → $39UpgradeHold → BuyGet Alert
10/06/2023Buy Now56.66%JP Morgan
Chris Schott59%
$39 → $36MaintainsNeutralGet Alert
10/02/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75ReiteratesOverweight → OverweightGet Alert
09/18/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75ReiteratesOverweight → OverweightGet Alert
09/13/2023Buy Now169.81%Truist Securities
Robyn Karnauskas55%
→ $62ReiteratesBuy → BuyGet Alert
09/05/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75ReiteratesOverweight → OverweightGet Alert
08/30/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75ReiteratesOverweight → OverweightGet Alert
08/22/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75ReiteratesOverweight → OverweightGet Alert
08/02/2023Buy Now169.81%Truist Securities
Robyn Karnauskas55%
$64 → $62MaintainsBuyGet Alert
08/02/2023Buy Now74.07%Morgan Stanley
Terence Flynn66%
$42 → $40MaintainsEqual-WeightGet Alert
08/02/2023Buy Now91.48%BMO Capital
Evan David Seigerman45%
$45 → $44MaintainsOutperformGet Alert
07/21/2023Buy Now82.77%Morgan Stanley
Terence Flynn66%
$43 → $42MaintainsEqual-WeightGet Alert
07/14/2023Buy Now117.59%HSBC
Rajesh Kumar63%
→ $50Initiates → BuyGet Alert
07/11/2023Buy Now87.12%Morgan Stanley
Terence Flynn66%
$43 → $43ReiteratesEqual-Weight → Equal-WeightGet Alert
07/11/2023Buy Now65.36%Barclays
Carter Gould59%
$40 → $38MaintainsEqual-WeightGet Alert
06/29/2023Buy Now74.07%Credit Suisse
Trung Huynh66%
$47 → $40DowngradeOutperform → NeutralGet Alert
06/23/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
$75 → $75ReiteratesOverweight → OverweightGet Alert
06/22/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75ReiteratesOverweight → OverweightGet Alert
05/17/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75ReiteratesOverweight → OverweightGet Alert
05/11/2023Buy Now65.36%Daiwa Capital
Narumi Nakagiri23%
$51 → $38DowngradeOutperform → NeutralGet Alert
05/03/2023Buy Now104.53%Credit Suisse
Trung Huynh66%
$50 → $47MaintainsOutperformGet Alert
05/03/2023Buy Now74.07%Barclays
Carter Gould59%
$43 → $40MaintainsEqual-WeightGet Alert
04/21/2023Buy Now95.83%B of A Securities
Geoff Meacham62%
$50 → $45MaintainsNeutralGet Alert
04/12/2023Buy Now87.12%Barclays
Carter Gould59%
$44 → $43MaintainsEqual-WeightGet Alert
04/10/2023Buy Now91.48%Morgan Stanley
Terence Flynn66%
$45 → $44MaintainsEqual-WeightGet Alert
03/17/2023Buy Now91.48%Wells Fargo
Mohit Bansal70%
$50 → $44MaintainsEqual-WeightGet Alert
03/06/2023Buy Now87.12%Jefferies
Akash Tewari43%
→ $43Initiates → HoldGet Alert
02/07/2023Buy Now121.94%Daiwa Capital
Narumi Nakagiri23%
→ $51UpgradeNeutral → OutperformGet Alert
02/01/2023Buy Now95.83%Morgan Stanley
Terence Flynn66%
$53 → $45MaintainsEqual-WeightGet Alert
02/01/2023Buy Now226.38%Cantor Fitzgerald
Louise Chen54%
→ $75Reiterates → OverweightGet Alert
02/01/2023Buy Now117.59%Credit Suisse
Trung Huynh66%
$54 → $50MaintainsOutperformGet Alert
02/01/2023Buy Now130.64%BMO Capital
Evan David Seigerman45%
$55 → $53MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Pfizer (PFE) stock?

A

The latest price target for Pfizer (NYSE:PFE) was reported by Cantor Fitzgerald on April 22, 2025. The analyst firm set a price target for $24.00 expecting PFE to rise to within 12 months (a possible 4.44% upside). 37 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Pfizer (PFE)?

A

The latest analyst rating for Pfizer (NYSE:PFE) was provided by Cantor Fitzgerald, and Pfizer initiated their neutral rating.

Q

When was the last upgrade for Pfizer (PFE)?

A

The last upgrade for Pfizer Inc happened on August 8, 2024 when Daiwa Capital raised their price target to $34. Daiwa Capital previously had a neutral for Pfizer Inc.

Q

When was the last downgrade for Pfizer (PFE)?

A

The last downgrade for Pfizer Inc happened on April 8, 2025 when Goldman Sachs changed their price target from $32 to $25 for Pfizer Inc.

Q

When is the next analyst rating going to be posted or updated for Pfizer (PFE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on April 22, 2025 so you should expect the next rating to be made available sometime around April 22, 2026.

Q

Is the Analyst Rating Pfizer (PFE) correct?

A

While ratings are subjective and will change, the latest Pfizer (PFE) rating was a initiated with a price target of $0.00 to $24.00. The current price Pfizer (PFE) is trading at is $22.98, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch